



**NOW
VIRTUAL**



PRELIMINARY PROGRAM Call for Abstracts / Scientific Program

WFSBP Congress 2021

15th World Congress of Biological Psychiatry

**Precision Psychiatry in the Era of Artificial
Intelligence and New Technologies**

28 – 30 June 2021

www.wfsbp-congress.org

Organized by: World Federation of Societies of Biological Psychiatry

Hosted by ÖGBP – Österreichische Gesellschaft für Neuropsychopharmakologie
und Biologische Psychiatrie

Table of Contents

Page

3	Invitation to the 15th World Congress of Biological Psychiatry
4	About WFSBP
5	Committees Congress Administration WFSBP Executive Committee International Scientific Program Committee Honorary Committee (HC) National Presidents Chairs of the Local Organizing Committee (LOC) Congress Ambassadors
	Congress Program
6	Colour Legend
7	Preliminary Scientific Program Schedule
10	Preliminary Scientific Program
29	Topics
30	Call for Abstracts for Free Communications and Posters
32	Format Descriptions of the Scientific Sessions
33	WFSBP Awards
34	Congress Information
35	General Information

Contact Details

WFSBP GLOBAL HEADQUARTERS

Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49-40-670 882 90
Fax: +49-40-670 328 82 91
Email: info@wfsbp.org
www.wfsbp-congress.org

CONGRESS AND EXHIBITION OFFICE

CPO[®]
HANSER
SERVICE

Phone: +49-30-300 669-0
wfsbp2021@cpo-hanser.de

Get the free Congress App for your smartphone

The WFSBP 2021 Congress App will be free of charge for congress participants and provide iPhone/iPad, Android, and other smartphone users at WFSBP 2021 with on-the-go access to the congress. The most up-to-date congress schedule will be available at your fingertips during the congress.

- Mark your favourite sessions and personalize your experience.
- Find information on sponsors and exhibitors involved in the WFSBP Congress 2021
- Access vital information around the congress.



The WFSBP 2021 App will be powered by GLOBIT GmbH.

Invitation to the 15th World Congress of Biological Psychiatry



Lakshmi N. Yatham

Dear Colleagues

On behalf of the executive committee of the World Federation of the Societies of Biological Psychiatry (WFSBP), we are delighted to invite you to attend the 15th World Congress of Biological Psychiatry. As a result of the current pandemic situation, the 15th World Congress of Biological Psychiatry will now be delivered as a virtual event for 3 days from 28–30 June 2021. By going virtual, WFSBP is contributing not only to reducing the risk of spread of COVID-19 but also eliminating CO2 emissions and reducing waste.

This is an exciting opportunity for the global biological psychiatry world to experience this innovative methodology for the first time. The registration fees have been reduced considerably in order to make it attractive for all delegates to participate in this exciting event. Please note that all sessions will not only be available online for the 3 congress days, but also for 2 months after the congress.

“Precision Psychiatry in the Era of Artificial Intelligence and New Technologies” is the major theme of this Congress. The Congress will feature plenaries, symposia, workshops and posters that will highlight the advances in the fields of drug discovery, genomics, imaging, omics, cognitive neuroscience, digital and clinical phenotyping, e-mental health and virtual care, and how artificial intelligence can leverage such advances to aid personalized treatment of people with mental disorders and addictions.

We very much look forward to welcoming you to the WFSBP World Congress.



Siegfried Kasper



Prof. Lakshmi N. Yatham
WFSBP President



Prof. Peter Falkai
Chair of the Scientific
Program Committee




Prof. Siegfried Kasper
Chair of the Regional
Organizing Committee

About WFSBP

Founded in 1974 in Buenos Aires, Argentina, the World Federation of Societies of Biological Psychiatry is a non-profit world wide organization composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.

With this multitude of countries represented in its world-wide community, the World Federation has built an international network of over 4,400 opinion leaders, the majority of which are key opinion-leaders in the practice of Biological Psychiatry.

WFSBP members by continent



As of October 2020




The principal objectives of WFSBP are:

- ▶ To foster and encourage scientific research and advancement in the field of Biological Psychiatry
- ▶ To improve the quality of training spanning all the biological psychiatry sciences
- ▶ To promote education and achieve the highest level of knowledge and understanding within the field
- ▶ To provide information and guidance to all institutions, societies or individuals with an interest in Biological Psychiatry
- ▶ To establish, build, and maintain solid collaboration with international and national organizations related to Biological Psychiatry

Educational activities, regional, international and world congresses, the interactive website www.wfsbp.org, and The World Journal of Biological Psychiatry build the World Federation's portfolio and ensure its worldwide influence. The development of worldwide treatment guidelines is one of WFSBP's main areas of international leadership.

Year after year, more and more professionals choose to join the World Federation's Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities.

WFSBP members by field of activity:



Committees

CONGRESS ADMINISTRATION

The 15th World Congress of Biological Psychiatry will be organized by the World Federation of Societies of Biological Psychiatry (WFSBP).

WFSBP EXECUTIVE COMMITTEE

President (2019 – 2023)

Lakshmi N. Yatham, Canada

Vice President (2017 – 2021)

Peter Falkai, Germany

Secretary (2017 – 2021)

Michael Berk, Australia

Vice Secretary (2017 – 2021)

Frederico Duarte Garcia, Brazil

Treasurer (2017 – 2021)

Dimitris Dikeos, Greece

Vice Treasurer (2017 – 2021)

Alejo Corrales, Argentina

INTERNATIONAL SCIENTIFIC PROGRAM COMMITTEE (ISPC)

Chair

Peter Falkai, Germany

Co-Chairs

Michael Berk, Australia

Matcheri Keshavan, USA

Members

Deanna Barch, USA

Ted Dinan, Ireland

Sophia Frangou, USA

Sidney Kennedy, Canada

Mario Maj, Italy

Brenda Penninx, The Netherlands

Marcella Rietschel, Germany

Gerard Sanacora, USA

Soraya Seedat, South Africa

Venkat Subramaniam, India

Trisha Suppes, USA

Masatoshi Takeda, Japan

Lisia von Diemen, Brazil

Gang Wang, China

Gregers Wegener, Denmark

Til Wykes, UK

HONORARY COMMITTEE (HC)

Jules Angst, Switzerland

Jose Luis Ayuso, Spain

Jorge Ciprian-Ollivier, Argentina

Jorge Alberto Costa e Silva, Brazil

Tetsuo Fukuda, Japan

Gerardo Heinze, Mexico

Carlos Roberto Hojaij, Brazil

Florian Holsboer, Germany

Siegfried Kasper, Austria

Jeffrey Lieberman, USA

Julien Mendlewicz, Belgium

Hans-Jürgen Möller, Germany

Robin Murray, UK

Ahmed Okasha, Egypt

Mitsumoto Sato, Japan

Norman Sartorius, Switzerland

Göran Sedvall, Sweden

Florence Thibaut, France

Michael Trimble, UK

NATIONAL PRESIDENTS

Alejo Corrales, Argentina

Anna Boyajyan, Armenia

Christian Geretsegger, Austria

Bernhard Sabbe, Belgium

Nils D. Noya-Tapia, Bolivia

Alma Bravo Mehmedbašić, Bosnia-Herzegovina

Antonio Marcolin, Brazil

Olya Atanasova Mikova-Demireva, Bulgaria

Raymond W. Lam, Canada

Alexei Franulic, Chile

Cesar Arango-Davila, Columbia

Rigoberto Castro, Costa Rica

Miro Jakovljevic, Croatia

Ladislav Hosak, Czech Republic

Gregers Wegener, Denmark

Fior Solis de Mendez, Dominican Republic

Juan Montenegro, Ecuador

Ahmed Okasha, Egypt

Manuel Meija Pena, El Salvador

Jaanus Harro, Estonia

Emmanuel Haffen, France

Jürgen Deckert, Germany

Constantin Soldatos, Greece

Hugo Soto Chavez, Guatemala

Mario Aguilar Lopez, Honduras

Michael Wong Ming Cheuk, Hong Kong

Csaba Banki, Hungary

G. Prasad Rao, India

Andi J. Tanra, Indonesia

Yoav Kohn, Israel

Mario Maj, Italy

Norio Ozaki, Japan

Marat Assimov, Kazakhstan

Yong-Ku Kim, Republic of Korea

Biruta Kupca, Latvia

Charles Baddoura, Libanon

Vesta Steibliene, Lithuania

Wah Yun Low, Malaysia

Driss Moussaoui, Morocco

Germán Villanueva Colín, Mexico

Hans Lovdahl, Norway

Mohammad Amin, Pakistan

Gaspar Da Costa, Panama

Liliana Rendon, Paraguay

Enrique Galli, Peru

Paweł Mierzejewski, Poland

Joao M. Teixeira, Portugal

Sergei Mosolov, Russia

Nadja Maric Bojovic, Serbia

Livia Vavrusova, Slovakia



Committees / Colour Legend

Soraya Seedat, South Africa
Ana González-Pinto Arrillaga, Spain
Carl Sellgren, Sweden
Jean-Michel Aubry, Switzerland
Yen-Kuang Yang, Taiwan
Pichet Udomratn, Thailand
Bilgen Taneli, Turkey
Allan V. Kalueff, Ukraine
Graciela Bouza de Suaya, Uruguay
Jorge Ibáñez-Domínguez, Venezuela

REGIONAL ORGANIZING COMMITTEE (ROC)

Chair

Siegfried Kasper, Austria

Members of ROC

Celso Arango, Spain
Judith Balázs, Hungary
Istvan Bitter, Hungary
Jürgen Deckert, Germany
Katharina Domschke, Germany
Dominika Dudek, Poland
Konstantinos Fountoulakis, Greece
Martin Hatzinger, Switzerland
Sabine Herpertz, Germany
Cyril Hoeschl, Slovakia
Alex Hofer, Austria
Edith Holsboer-Trachsler,
Switzerland
Marek Jarema, Poland

Hans-Peter Kapfhammer, Austria
Tomas Kasperek, Slovakia
Tamas Kurimay, Hungary
Rupert Lanzenberger, Austria
Mario Maj, Italy
Nadja Maric, Serbia
Josef Marksteiner, Austria
Andreas Meyer-Lindenberg,
Germany
Petr Morozov, Russia
János Réthelyi, Hungary
Dan Rujescu, Germany
Gabriele Sachs, Austria
Jerzy Samochowiec, Poland
Agata Szulc, Poland
Erich Seifritz, Switzerland
Alessandro Serretti, Italy
Eva Ceskova, Slovakia
Eduard Vieta, Spain

COLOUR CODES OF SESSIONS (PRELIMINARY SCIENTIFIC PROGRAM, PAGES 10 – 28)



Plenary Lectures



Debates



Task Force Symposia



Symposia



Workshops



Satellite Symposia



Educational Sessions

Monday, 28 June 2021 / Preliminary Scientific Program Schedule

7:30	S-01 Anti-inflammatory approaches to major mental disorders	S-02 Cognitive impairment and negative symptoms in schizophrenia	S-03 Immune gate to psychopathology and treatment of depression	S-04 Psychedelics, dissociatives and altered states of consciousness, hot topics in psychiatry and brain research	S-05 Big biological data, data integration and learning algorithms in deciphering major depression and its treatments	ES-01 How to design a translational (clinical) study
8:00						
8:30						
9:00						
9:30	D-01 Should antipsychotic drugs be discontinued as early as possible after the first break – yes or no?	S-06 PTSD-focused eHealth interventions	S-07 In vitro models of psychiatric disorders	S-08 How safe are psychotropic drugs and ECT in pregnancy?	S-09 Novel psychoactive substances	TFS-01 Symposium of the WF SBP Task Force „Genetics“. Precision psychiatry in the era of new technologies
10:00						
10:30						
11:00						
11:30	Satellite Symposia					
12:00						
12:30						
13:00						
13:30	S-10 Metabolic syndrome in psychiatry: recognition and management of psychotropic drug induced metabolic effects	S-11 G protein-coupled receptors (GPCRs) heterocomplexes in the neuronal networks of the brain in health and disease	S-12 Health and environmental resilience: effects of urbanization and climate change on mental health	S-13 Issues in the clinical trials of new therapeutic agents: A joint WF SBP-WPA symposium	S-14 Key principles of sensorimotor dysfunction in mental disorders	S-15 Contextual modulation of anxiety
14:00						
14:30						
15:00						
15:30	S-16 Treatment of cognitive dysfunction in psychiatric disorders – a major unmet need	TFS-02 Identification of neuroprogressive profiles and course in recurrent affective disorders Part 1	S-17 Plasticity in depression: How synapses, networks and environment interact	S-18 Treatment Resistant Depression (TRD)	S-19 State-of-the-art stress assessments across a diverse range of use cases	ES-02 Understanding and performing meta-analysis
16:00						
16:30						
17:00						
17:30	Plenary Lecture PL-01 Synaptic mechanisms driving schizophrenia pathogenesis (Thomas Südhof, USA)					
18:00						
18:30						
19:00	Satellite Symposia					
19:30						
20:00						
20:30						

All sessions run in Central European Summer Time (CEST).

► **Exhibition and Poster Exhibition** – accessible all day



Preliminary Scientific Program Schedule / Tuesday, 29 June 2021

7:30	S-20 Are anti-inflammatory treatments really useful in depression?	S-21 OCD: Enigma wrapped in a riddle	S-22 Towards digital-based care of schizophrenia: Where are we heading?	S-23 COVID-19 and mental health: What do we know?	S-24 The microbiota-gut-brain axis in psychiatric disorders: Gene-environment interactions and therapeutic targets	S-25 Treatment and outcome of different clinical facets of Bipolar disorder
8:00						
8:30						
9:00						
9:30	D-02 The Amyloid Hypothesis is the key for a cure for Alzheimer's Disease	S-26 Purinergic mechanisms in psychiatric disorders	WS-01 Immune system and suicidal behaviour: What do we know?	S-27 Psychedelics – a way out of the box?	S-28 Pharmacogenomics and personalized medicine for antipsychotic and antidepressant medications: are we there yet?	ES-03 Understanding and designing genetic studies
10:00						
10:30						
11:00						
11:30	Satellite Symposia					
12:00						
12:30						
13:00						
13:30	TFS-03 Tools for optimizing pharmacotherapy in psychiatry: Focus on antipsychotics	TFS-04 Psychopathology in times of precision psychiatry	S-29 Nature and nurture in suicidal behaviour: latest updates	S-30 Update on the WFSBP guidelines for the Pharmacological Treatment of Eating Disorders	S-31 Can translational research enhance the efficacy of rTMS in MDD?	ES-04 Basics of biostatistics
14:00						
14:30						
15:00						
15:30	Plenary Lecture PL-02 Interpersonal psychotherapy – A global reach (Myrna Weissman, USA)					
16:00						
16:30						
17:00	S-32 ENIGMA and the PGC: Large-scale studies of psychiatric genetics and brain imaging	TFS-05 Identification of neuro-progressive profiles and course in recurrent affective disorders Part 2	WS-02 Next-step treatment considerations in patients with treatment-resistant depression that respond to low-dose intravenous ketamine	S-33 Canadian Network for Mood and Anxiety treatments (CANMAT): update of novel treatments and approaches for Bipolar Disorder	S-34 Precision psychiatry: The case of treatment resistant schizophrenia	S-35 Clearing the smoke: Cannabis, Mood Disorders and Schizophrenia. A CANMAT Symposium
17:30						
18:00						
18:30						
19:00	Satellite Symposia					
19:30						
20:00						
20:30						

All sessions run in Central European Summer Time (CEST).

► Exhibition and Poster Exhibition – accessible all day

Wednesday, 30 June 2021 / Preliminary Scientific Program Schedule

7:30	S-36 The genomics of severe depression and ECT	S-37 Electroconvulsive therapy in Austria	S-38 Minocycline in psychiatry	S-39 From fieldwork to battlefield: novel insights into the neurobiology of understanding, predicting and treating suicidal behaviour	S-40 Involvement of the immune system in schizophrenia, depression and anxiety disorders	S-41 Neurotrophins and their role in anti-depressive therapy
8:00						
8:30						
9:00						
9:30	Plenary Lecture					
10:00	PL-03 Cannabis: the good, the bad, and the mad (Robin Murray, United Kingdom)					
10:30						
11:00	D-03 Are psychedelic drugs useful in the treatment of psychiatric disorders?	S-42 Drug level monitoring with a focus on perinatal disorders: Clinical and research dilemmas	S-43 Staging of psychosis: Vision and challenges	S-44 Metabolic perspective on neurocognition and illness progression in Bipolar Disorder	S-45 Appetite regulating peptides – an innovative neuroendocrinological therapy strategy for relapse prevention and craving in patients suffering from alcohol use disorder and tobacco dependence?	S-46 Computerized procedures supporting diagnostics in psychiatry: using AI to develop novel biomarker and diagnostic tool for psychiatric research and clinical practice
11:30						
12:00						
12:30						
					11:00–12:30	11:00–12:30
13:00	Satellite Symposia					
13:30						
14:00						
14:30						
15:00	S-47 hiPSC technology: new approaches to dissect the molecular genetic mechanisms underlying schizophrenia	S-48 RNA biology in neuropsychiatry: From novel technologies to future precision psychiatry	S-49 Recognizing and treating non-classical forms of Bipolar Disorder	TFS-06 Stress and suicide in men in the COVID-19 era	S-50 Electroconvulsive Therapy beyond depression: specific populations and (yet) rare indications	ES-05 Understanding and designing imaging studies
15:30						
16:00						
16:30						
17:00	Plenary Lecture					
17:30	PL-04 Stem cells in mental disorders: new understanding and treatment (Kristen Brennand, USA)					
18:00						
18:30	S-51 Behavioral addictions: Brain imaging findings and their translation to clinical practice	S-52 Biomarkers of response to IV Ketamine for depression	TFS-07 Violence and men: Recent research and clinical aspects	S-53 Chronobiology: from basic concepts to clinical practice in mood disorders	S-54 Benefit of Ketamine in clinical practice: Current perspectives	S-55 The present and future of biological psychiatry through the eyes of residents
19:00						
19:30						
20:00						
20:30						

All sessions run in Central European Summer Time (CEST).

► Exhibition and Poster Exhibition – accessible all day

Preliminary Scientific Program / Plenary Lectures, Debates

Plenary Lectures

► Monday, 28 June 2021

PL-01

17:30–18:30

Synaptic mechanisms driving schizophrenia pathogenesis

Thomas Südhof, USA



► Tuesday, 29 June 2021

PL-02

15:30–16:30

Interpersonal psychotherapy – A global reach

Myrna Weissman, USA

► Wednesday, 30 June 2021

PL-03

09:30–10:30

Cannabis: the good, the bad, and the mad

Robin Murray, United Kingdom

PL-04

17:00–18:00

Stem cells in mental disorders: new understanding and treatment

Kristen Brennand, USA

Debates

► Monday, 28 June 2021

D-01

09:30–11:00

Should antipsychotic drugs be discontinued as early as possible after the first break – yes or no?

Proponent: Merete Nordentoft, Denmark

Opponent: Robin Emsley, South Africa

► Tuesday, 29 June 2021

D-02

09:30–11:00

The Amyloid Hypothesis is the key for a cure for Alzheimer's Disease

Proponent: Christian Haass, Germany

Opponent: TBD

► Wednesday, 30 June 2021

D-03

11:00–12:30

Are psychedelic drugs useful in the treatment of psychiatric disorders?

Proponent: TBD

Opponent: Ted Dinan, Ireland

WFSBP Task Force Symposia / Preliminary Scientific Program

WFSBP Task Force Symposia

► **Monday, 28 June 2021**

T22: GENETICS

TFS-01

09:30–11:00

Symposium of the WFSBP Task Force „Genetics“. Precision Psychiatry in the Era New Technologies

Chair: Dan Rujescu, Germany

Co-Chair: Mick O'Donovan, United Kingdom

TFS-01-001

The PGC Schizophrenia genome wide associations study including over 300.000 patients and controls

Mick O'Donovan, United Kingdom

TFS-01-002

Genomics of clozapine-induced neutropenia and agranulocytosis

Dan Rujescu, Germany

TFS-01-003

Pharmacogenetics on response and side effects in schizophrenia and in depression

Jim Kennedy, Canada

TFS-01-004

Clinical and genetic characteristics of treatment-resistant depression in UK biobank

Chiara Fabbri, United Kingdom

T14: DEPRESSION: BASIC / CLINICAL

TFS-02

15:30–17:00

Identification of neuroprogressive profiles and course in recurrent affective disorders – Part 1

Chair: Angelos Halaris, USA

Co-Chair: TBD

TFS-02-001

Identification of neuroprogressive profiles and course in recurrent affective disorders

Flavio Kapszinski, Canada

TFS-02-002

Identification of neuroprogressive profiles and course in recurrent affective disorders

Bianca Pfaffenseller, Canada

TFS-02-003

Identification of neuroprogressive profiles and course in recurrent affective disorders

Vicente Balanza, Spain

TFS-02-004

Identification of neuroprogressive profiles and course in recurrent affective disorders

Dimitris Dikeos, Greece

► **Tuesday, 29 June 2021**

T49: PSYCHOPHARMACOLOGY

TFS-03

13:30–15:00

Tools for optimizing pharmacotherapy in psychiatry: Focus on antipsychotics

Chair: Christoph Hiemke, Germany

Co-Chair: Gerhard Gründer, Germany

TFS-03-001

TDM of antipsychotics: General principles

Georgios Schoretsantis, United States

TFS-03-002

PET imaging for dose selection of antipsychotics

Hirokyu Uchida, Japan

TFS-03-003

Utility of genetic tools in antipsychotics dose personalization

Marin Jukic, Sweden

TFS-03-004

Use of TDM, phenotyping and genotyping tests in a psychiatric hospital: The example of the Lausanne University Hospital

Chin B. Eap, Switzerland

T48: PSYCHOPATHOLOGY

TFS-04

13:30–15:00

Psychopathology in times of precision psychiatry

Chair: Wolfgang Gaebel, Germany

Co-Chair: Veronica Larach, Chile

TFS-04-001

The WFSBP Psychopathology Position Paper 2010: 10 years later and the future ahead

Michael Musalek, Austria

TFS-04-002

Psychopathology in DSM-5, ICD-11, new classification approaches (RDoC, HiTOP), and beyond

Wolfgang Gaebel, Germany

TFS-04-003

Telepsychiatry and psychopathology – opportunities and challenges

Veronica Larach, Chile

Preliminary Scientific Program / WFSBP Task Force Symposia

TFS-04-004

Psychopathology in person-centred, personalized, and precision psychiatry

Andrea Raballo, Italy

T14: DEPRESSION: BASIC/CLINICAL

TFS-05

17:00–18:30

Identification of neuroprogressive profiles and course in recurrent affective disorders – Part 2

Chair: Angelos Halaris, USA

Co-Chair: TBD

TFS-05-001

Identification of neuroprogressive profiles and course in recurrent affective disorders

Jeffrey Meyer, Canada

TFS-05-002

Identification of neuroprogressive profiles and course in recurrent affective disorders

Ghanshyam Pandey, USA

TFS-05-003

Identification of neuroprogressive profiles and course in recurrent affective disorders

Bianca Wollenhaupt de Aguiar, Canada

► Wednesday, 30 June 2021

T59: SUICIDE: BASIC/CLINICAL

TFS-06

15:00–16:30

Stress and suicide in men in the COVID-19 era

Chair: Leo Sher, USA

Co-Chair: Zoltan Rihmer, Hungary

TFS-06-001

Why suicide is more common in males?

Zoltan Rihmer, Hungary

TFS-06-002

The impact of the COVID-19 pandemic on suicide rates in men

Leo Sher, USA

TFS-06-003

The psychosocial effects of containment measures, social distancing and quarantine related to the COVID-19 pandemic

Gianluca Serafini, Italy

TFS-06-004

Responses of male youth with psychiatric disorders to caretaker incapacitation: Applications or the COVID-19 era

Timothy Rice, USA

T60: VIOLENCE: BASIC/CLINICAL

TFS-07

18:30–20:00

Violence and men: Recent research and clinical aspects

Chair: Timothy Rice, USA

Co-Chair: Andreas Walther, Switzerland

TFS-07-001

Response to blood scent as potential marker of appetitive vs. reactive aggression in men and women

James Moran, Germany

TFS-07-002

What's weed got to do with it? Cannabis use and aggressive behavior in men

Sierra Ferguson, USA

TFS-07-003

Looking for trouble: Aggressive and dominant men feel they have all eyes on them

Janek Lobmaier, Switzerland

TFS-07-004

Aggressive men?: Examining psychobiological factors driving aggression and aggressive behavior in men

Andreas Walther, Switzerland

Symposia / Preliminary Scientific Program

Symposia

► Monday, 28 June 2021

T49: PSYCHOPHARMACOLOGY

S-01

07:30–09:00

Anti-inflammatory approaches to major mental disorders

Chair: Olivia Dean, Australia

Co-Chair: Ishrat Husain, Canada

Co-Chair: Imran B. Chaudhry, Pakistan

S-01-001

Anti-inflammatory approaches to treat schizophrenia

Omar Husain, Canada

S-01-002

Anti-inflammatory approaches to treat depression

Golam Khandaker, United Kingdom

S-01-003

Anti-inflammatory approaches to treat anxiety

Dan Stein, South Africa

S-01-004

Anti-inflammatory to treat Bipolar Disorder

Olivia Dean, Australia

T52: SCHIZOPHRENIA AND OTHER PSYCHOSIS: BASIC / CLINICAL

S-02

07:30–09:00

Cognitive impairment and negative symptoms in schizophrenia

Chair: Gabriele Sachs, Austria

Co-Chair: Istvan Bitter, Hungary

S-02-001

Cognitive impairment and real-life functioning in schizophrenia

Armida Mucci, Italy

S-02-002

Neuronal correlates of negative symptoms

Eva Meisenzahl, Germany

S-02-003

Negative symptoms and treatment outcomes in schizophrenia

Istvan Bitter, Hungary

S-02-004

Therapeutic interventions for cognitive impairment in schizophrenia

Gabriele Sachs, Austria

T14: DEPRESSION: BASIC / CLINICAL

S-03

07:30–09:00

Immune gate to psychopathology and treatment of depression

Chair: Agata Szulc, Poland

Co-Chair: Kuan-Pin Su, Taiwan

S-03-001

Neuroinflammation, kynurenine pathway and depression

Agata Szulc, Poland

S-03-002

Intestinal microbiota as cytokines' modulators of the immune gate of psychopathology

Leszek Rudzki, United Kingdom

S-03-003

Omega-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression

Kuan-Pin Su, Taiwan

S-03-004

Efficacy of anti-inflammatory agents for the treatment of major depression

Piotr Galecki, Poland

T49: PSYCHOPHARMACOLOGY

S-04

07:30–09:00

Psychedelics, dissociatives and altered states of consciousness, hot topics in psychiatry and brain research

Chair: Tomas Palenicek, Czech Republic

Co-Chair: Kim Kuypers, The Netherlands

S-04-001

Neural correlates of pharmacologically vs. non-pharmacologically induced altered states: Changes in the brain connectivity under LSD, psilocybin, hypnosis and meditation

Nathalie Rieser, Switzerland

S-04-002

Psilocybin induced changes in brain entropy and the dimension of the experience predict long-term positive effects on mood in healthy volunteers

Tomas Palenicek, Czech Republic

Preliminary Scientific Program / Symposia

S-04-003

The effects of LSD microdosing on cognitive, subjective and biological parameters in healthy volunteers

Kim Kuypers, The Netherlands

S-04-004

Clinical and neurobiological predictors of antidepressant response to Ketamine

Jiri Horacek, Czech Republic

T14: DEPRESSION: BASIC / CLINICAL

S-05

07:30–09:00

Big biological data, data integration and learning algorithms in deciphering major depression and its treatments

Chair: Gabriella Juhasz, Hungary

Co-Chair: Hiroshi Mamitsuka, Japan

S-05-001

Health risk assessment in somatic and mental comorbidities: Population based studies in Catalonia

Isaac Cano, Spain

S-05-002

Gene-environment interactions as stratification variables behind depression

Sandra van der Auwera-Palitschka, Germany

S-05-003

Effects of polymorphisms depend on stress exposure: An example of the use of Bayesian learning algorithms

Xenia Gonda, Hungary

S-05-004

Machine learning for predicting drug-target interactions

Hiroshi Mamitsuka, Japan

T41: POST TRAUMATIC STRESS DISORDERS

S-06

09:30–11:00

PTSD-focused eHealth interventions

Chair: Soraya Seedat, South Africa

Co-Chair: Miranda Olf, The Netherlands

S-06-001

Development and use of the Global Psychotrauma Scale (GPS)

Miranda Olf, The Netherlands

S-06-002

Development of the COVID Coach mApp based PTSD Coach

Beth Jaworski, USA

S-06-003

Preliminary efficacy of a mental health self-management mApp for PTSD in clinicians during COVID-19

Leigh van den Heuvel, South Africa

S-06-004

Feasibility and acceptability of a clinician supported PTSD Coach intervention

Erine Bröcker, South Africa

T56: STEM CELLS AND ORGANIDS

S-07

09:30–11:00

In vitro models of psychiatric disorders

Chair: Vincent Millischer, Austria

Co-Chair: Carl Sellgren-Majkowitz, Sweden

S-07-001

Synapse refinement, organoids and schizophrenia

Carl Sellgren-Majkowitz, Sweden

S-07-002

Modelling affective disorders with induced pluripotent stem cells

Krishna Vadodaria, USA

S-07-003

Modelling prenatal maternal stress in organoids

Cristiana Cruceanu, Germany

S-07-004

Cerebral organoids to model neurodevelopmental disorders

Nina Corsini, Austria

T49: PSYCHOPHARMACOLOGY

S-08

09:30–11:00

How safe are psychotropic drugs and ECT in pregnancy?

Chair: Angelika Wieck, United Kingdom

Co-Chair: Ian Jones, United Kingdom

S-08-001

Why are reproductive safety data so difficult to interpret?: The example of antidepressants

Ian Jones, United Kingdom

S-08-002

What do we know about the effects of antipsychotics and mood stabilizers on the development of children exposed in utero?

Angelika Wieck, United Kingdom

Symposia / Preliminary Scientific Program

S-08-003

Obstetric and child outcomes after use of ECT in pregnancy

Anne-Laure Sutter, France

S-08-004

Preconception counselling for women taking psychotropic drugs: A UK approach

Elizabeth McDonald, Ireland

T1: ADDICTIVE DISORDER

S-09

09:30–11:00

Novel Psychoactive Substances (NPS)

Chair: Aviv Weinstein, Israel

Co-Chair: Liana Fattore, Italy

S-09-001

Short and long term effects of the ketamine-like analog metoxetamine: Insights into potential mechanisms of action

Liana Fattore, Italy

S-09-002

Synthetic cannabinoids: Convulsant effects

William Fantegrossi, USA

S-09-003

The effects of synthetic cannabinoids on cognitive function, brain imaging in fMRI and mental health

Aviv Weinstein, Israel

S-09-004

Pharmacological effects and toxicity of synthetic cathinones in humans

Magi Farré, Spain

T49: PSYCHOPHARMACOLOGY

S-10

13:30–15:00

Metabolic syndrome in psychiatry: Recognition and management of psychotropic drug induced metabolic effects

Chair: Chin B. Eap, Switzerland

Co-Chair: Christoph U. Correll, USA

S-10-001

Metabolic syndrome in psychiatry: An overview

Christoph U. Correll, USA

S-10-002

Clinical, genetic and epigenetic determinants of metabolic syndrome induced by psychotropic drugs

Chin B. Eap, Switzerland

S-10-003

The influence of exercise on body composition and the metabolic syndrome in severe mental illness

Kai G. Kahl, Germany

S-10-004

Exercise-based interventions for mental illness: Physical activity as part of clinical treatment

Brendon Stubbs, United Kingdom

T26: MOLECULAR NEUROBIOLOGY

S-11

13:30–15:00

G Protein-coupled Receptors (GPCRs) heterocomplexes in the neuronal networks of the brain in health and disease

Chair: Dasiel Oscar Borroto-Escuela, Sweden

Co-Chair: Kjell Fuxe, Sweden

S-11-001

Signaling at D2R.OxytocinR heterocomplexes and their relevance for the anxiolytic effects in the amygdala of the rat

Miguel Perez de la Mora, Mexico

S-11-002

Dopamine D2 heteroreceptor complexes in cocaine use disorder: Relevance for treatment

Karolina Wydra, Poland

S-11-003

Multiple D2 heteroreceptor complexes: New targets for treatment of schizophrenia

Luca Ferraro, Italy

S-11-004

Brain 5-HT1A heteroreceptor complexes in a rat model of depression and as targets for antidepressant treatment

Dasiel Oscar Borroto-Escuela, Sweden

T62: MISCELLANEOUS

S-12

13:30–15:00

Health and environmental resilience: Effects of urbanization and climate change on mental health

Chair: Alfonso Tortorella, Italy

Co-Chair: Gabriele Sachs, Austria

S-12-001

Climate change and mental health: An overview

Andreas Erfurth, Austria

Preliminary Scientific Program / Symposia

S-12-002

The ecological momentary assessment approach and the use of big data to analyze effects of climate change on mental health

Alfonso Tortorella, Italy

S-12-003

The role of resilience in the development of psychiatric disorders

Norma Verdolini, Spain

S-12-004

Effects of climate change on affective disorders: Towards a study of environmental resilience in Bipolar Disorder

Vigdis Elin Gjaever Syrtstad, Norway

T49: PSYCHOPHARMACOLOGY

S-13

13:30–15:00

Issues in the clinical trials of new therapeutic agents: A joint WFSBP-WPA symposium

Chair: Afzal Javed, United Kingdom

Co-Chair: Konstantinos Fountoulakis, Greece

S-13-001

Burning issues in the clinical trials with antidepressants

Konstantinos Fountoulakis, Greece

S-13-002

Contemporary problems of clinical studies of new anxiolytics and antidepressants

Timur Syunyakov, Russian Federation

S-13-003

Binding in clinical trials on the therapeutic effects of psychedelic substances

Gregor Hasler, Switzerland

S-13-004

Studying mechanisms in clinical trials: Challenges and opportunities in children and adolescents

Argyris Stringaris, USA

T29: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

S-14

13:30–15:00

Key principles of sensorimotor dysfunction in mental disorders

Chair: Dusan Hirjak, Germany

Co-Chair: Christian Wolf, Germany

S-14-001

Sensorimotor domain in psychiatric disorders: Evolution of the concept and classification

Dusan Hirjak, Germany

S-14-002

Sensorimotor abnormalities in psychotic disorders: Brain imaging and pathophysiological models

Christian Wolf, Germany

S-14-003

Sensorimotor dysfunction in a transnosological context

Katharina Kubery, Germany

S-14-004

Sensorimotor dysfunction as a target for non-invasive brain stimulation

Sebastian Walther, Switzerland

T5: ANXIETY DISORDERS: BASIC / CLINICAL

S-15

13:30–15:00

Contextual modulation of anxiety

Chair: Grit Hein, Germany

Co-Chair: Jan Haaker, Germany

S-15-001

Neuropharmacological mechanisms of threat and safety learning

Jan Haaker, Germany

S-15-002

Shared safety abolishes the recovery of learned threat

Armita Golkar, Sweden

S-15-003

Factors modulating the social buffering of human anxiety

Grit Hein, Germany

S-15-004

Responses to threat and safety in virtual contexts

Paul Pauli, Germany

Symposia / Preliminary Scientific Program

T14: DEPRESSION: BASIC/CLINICAL

S-17

15:30–17:00

Plasticity in depression: How synapses, networks and environment interact

Chair: Claus Normann, Germany

Co-Chair: Eero Castrén, Finland

S-17-001

Synaptic plasticity as pathomechanism of depression and target of antidepressant action

Claus Normann, Germany

S-17-002

Neuroplasticity, vulnerability and the environment

Igor Branchi, Italy

S-17-003

Sleep specific modulation of synaptic plasticity as antidepressant mechanism

Christoph Nissen, Switzerland

S-17-004

BDNF/TrkB receptors as antidepressant target

Eero Castrén, Finland

T14: DEPRESSION: BASIC/CLINICAL

S-18

15:30–17:00

Treatment Resistant Depression (TRD)

Chair: Siegfried Kasper, Austria

S-18-001

Characterization of treatment resistant depression in Europe

Siegfried Kasper, Austria

S-18-002

Genetic findings in TRD

Alessandro Serretti, Italy

S-18-003

Glutamatergic approach in TRD

Carlos Zarate, USA

S-18-004

Stimulation treatment methods in TRD

Thomas Schläpfer, Germany

T14: STRESS: BASIC/CLINICAL

S-19

15:30–17:00

State-of-the-Art stress assessments across a diverse range of use cases

Chair: Jörg Signerski-Krieger, Germany

Co-Chair: Wencke Chodan, Germany

S-19-001

Stress and alcohol addiction: Neurobiology, comorbidity and treatment

Dirk Wedekind, Germany

S-19-002

The effects of COVID-19 and the lockdown on the stress of patients with gender dysphoria

Jörg-Signerski-Krieger, Germany

S-19-003

Stress during online learning: A solution offered by the self-determination theory

Philipp Spitzer, Germany

S-19-004

Novel technological advances in objective stress assessment employing machine learning models

Mario Aehnelt, Germany

Preliminary Scientific Program / Symposia

► Tuesday, 29 June 2021

T14: DEPRESSION: BASIC / CLINICAL

S-20

07:30–09:00

Are anti-inflammatory treatments really useful in depression?

Chair: Olivia Dean, Australia

Co-Chair: Eduard Vieta, Spain

Co-Chair: Michael Berk, Australia

S-20-001

Anti-inflammatory treatments are useful for major depressive disorder

Roger McIntyre, Canada

S-20-002

Anti-inflammatory treatments are not useful for major depressive disorder

Charles Raison, USA

S-20-003

Anti-inflammatory treatments are useful for Bipolar Disorder

Olivia Dean, Australia

S-20-004

Anti-inflammatory treatments are not useful for Bipolar Disorder

Eduard Vieta, Spain

T33: OBSESSIVE-COMPULSIVE DISORDERS: BASIC / CLINICAL

S-21

07:30–09:00

OCD: Enigma wrapped in a riddle

Chair: Digvijay Goel, New Zealand

Co-Chair: Mohan Isaac, Australia

S-21-001

The hidden epidemic

Agata Golawska Moody, Poland

S-21-002

The aetiologic conundrum

Pratap Kovvuri, New Zealand

S-21-003

Diagnostic dilemmas

Aleksandra Antczak, United Kingdom

S-21-004

The bottom line

Mohan Isaac, Australia

T52: SCHIZOPHRENIA AND OTHER PSYCHOSIS: BASIC / CLINICAL

S-22

07:30–09:00

Towards digital-based care of schizophrenia: Where are we heading?

Chair: Taishiro Kishimoto, Japan

Co-Chair: John Torous, USA

S-22-001

Digital medicine in mental health: Opportunities and challenges

John Torous, USA

S-22-002

Utilization of smartphone application to strengthen and establish social relationships

Michelle Lim, Australia

S-22-003

Digital technology utilization in providing measurement-based care for psychosis

Daniel Guinart, USA

S-22-004

United States: Identifying early signs of psychosis based on social media posting and internet search histories

John Kane, USA

T51: SARS-COV-2

S-23

07:30–09:00

COVID-19 and mental health: What do we know?

Chair: Gil Zalsman, Israel

Co-Chair: Teo Postolache, USA

S-23-001

Effect of COVID-19 on physical and mental health: Initial results from the worldwide COH-FIT study

Christoph U. Corell, Germany

S-23-002

Sequential dual vulnerability – triggering at the core of neuropsychiatric manifestations in COVID-19

Teo Postolache, USA

S-23-003

Psychological impact of COVID-19 lockdown in psychiatric patients. Is loneliness a predictor?

Philippe Courtet, France

S-23-004

How COVID-19 influence suicide rates?

Gil Zalsman, Israel

Symposia / Preliminary Scientific Program

T32: NUTRITIONAL PSYCHIATRY AND THE MICROBIOME

S-24

07:30–09:00

The microbiota-gut-brain axis in psychiatric disorders: Gene-environment interactions and therapeutic targets

Chair: Anthony Hannan, Australia

Co-Chair: Rochellys Diaz Heijtz, Sweden

S-24-001

Drugs from bugs: The potential of the microbiome in mental illness

Valerie Taylor, Canada

S-24-002

The microbiota and immune system crosstalk in neuro-development and behavior

Rochellys Diaz Heijtz, Sweden

S-24-003

Microbiome and the social brain: Relevance to psychiatry

Nathaniel Ritz, Ireland

S-24-004

Gene-environment interactions modulating the microbiota-gut-brain axis in preclinical models of psychiatric disorders

Anthony Hannan, Australia

T8: BIPOLAR DISORDERS: BASIC / CLINICAL

S-25

07:30–09:00

Treatment and outcome of different clinical facets of Bipolar Disorder

Chair: Konstantinos Fountoulakis, Greece

Co-Chair: Allan Young, United Kingdom

S-25-001

Mechanisms of antidepressant effect in the treatment of bipolar depression

Konstantinos Fountoulakis, Greece

S-25-002

Chronic and subsyndromal Bipolar Disorder

Heinz Grunze, Germany

S-25-003

Treating cognitive impairment in Bipolar Disorder

Allan Young, United Kingdom

S-25-004

Somatic burden, Bipolar Disorder symptoms and functional outcome in older-age Bipolar Disorder: Emerging insights from the Global Aging & Geriatric Experiments in Bipolar Disorder Database project (GAGE-BD)

Martha Sajatovic, USA

T49: PSYCHOPHARMACOLOGY

S-26

09:30–11:00

Purinergic mechanisms in psychiatric disorders

Chair: Beata Sperlagh, Hungary

Co-Chair: Peter Illes, Germany

S-26-001

Involvement of ATPergic mechanisms in psychiatric and neurological diseases

Peter Illes, Germany

S-26-002

Understanding P2X7R function in stress-related disorders

Jan Deussing, Germany

S-26-003

The role of P2X7 and neuroinflammation in psychiatric disorders

Anindya Bhattacharya, USA

S-26-004

P2X7 receptor: A new therapeutic target to intervene disrupted neuronal development and to combat autism spectrum disorder

Beata Sperlagh, Hungary

T49: PSYCHOPHARMACOLOGY

S-27

09:30–11:00

Psychedelics – a way out of the box?

Chair: Erich Seifritz, Switzerland

Co-Chair: Franz Vollenweider, Switzerland

S-27-001

Efficacy and safety of psilocybin in treatment-resistant depression (the EPIsoDE trial): Background, study design and first results

Gerhard Gründer, Switzerland

S-27-002

Developing pharmacohuasca applications for mental health

Milan Scheidegger, Switzerland

Preliminary Scientific Program / Symposia

S-27-003

GHB – psychotherapy enhancement project

Oliver Bosch, Switzerland

S-27-004

Cognitive and emotional mechanisms underlying antidepressant effects of psychedelics

Franz Vollenweider, Switzerland

T39: PHARMACOGENETICS

S-28

09:30–11:00

Pharmacogenomics and personalized medicine for antipsychotic and antidepressant medications: Are we there yet?

Chair: Bernhard Baune, Germany

Co-Chair: Alessandra Minelli, Italy

S-28-001

Pharmacogenomics – end of road or new horizons?

Bernhard Baune, Germany

S-28-002

A clinical perspective on pharmacogenetic testing of antidepressants

Alessandro Serretti, Italy

S-28-003

Pharmacogenetic applications for antipsychotic medications

Daniel Mueller, Canada

S-28-004

Clinical phenotypes characterization in clinical pharmacological trials: Past, present, future

Alessandra Minelli, Italy

T59: SUICIDE: BASIC/CLINICAL

S-29

13:30–15:00

Nature and Nurture in suicidal behaviour: Latest updates

Chair: Dan Rujescu, Germany

Co-Chair: John Mann, USA

S-29-001

Latest genome wide studies on suicidal behaviour and intermediate phenotypes

Dan Rujescu, Germany

S-29-002

Genomic and protein mediation of effects of childhood adversity on suicide risk

John Mann, USA

S-29-003

Mediating effect of genome-wide DNA methylation on suicidal ideation included by stressful events

Vincenzo De Luca, Canada

S-29-004

Polygenic risk score for major depressive disorder is associated with suicide attempt

Alessandro Serretti, Italy

T17: EATING DISORDER: BASIC/CLINICAL

S-30

13:30–15:00

Update on the WFSBP guidelines for the pharmacological treatment of eating disorders

Chair: Janet Treasure, United Kingdom

Co-Chair: Siegfried Kasper, Austria

S-30-001

Recommendations of the WFSBP guidelines update on pharmacological treatment of eating disorders

Hubertus Himmerich, United Kingdom

S-30-002

Pharmacological treatment for patients with anorexia nervosa

Yael D. Lewis, Israel

S-30-003

Pharmacological treatment for patients with bulimia nervosa and binge-eating disorder

Chiara Conti, Italy

S-30-004

Pharmacogenetics and pharmacokinetics of medications for the treatment of eating disorders

Daniel J. Müller, Canada

T42: PRECISION PSYCHIATRY

S-31

13:30–15:00

Can translational research enhance the efficacy of rTMS in MDD?

Chair: Roberto Goya-Maldonado, Germany

Co-Chair: Chris Baeken, Belgium

S-31-001

Concurrent rTMS/fMRI for target engagement monitoring

Christian Windischberger, Austria

S-31-002

Differential effects of iTBS and 10Hz rTMS protocols on the DMN

Roberto Goya-Maldonado, Germany

Symposia / Preliminary Scientific Program

S-31-003

Accelerated iTBS treatment in depressed patients results in left hippocampal volume increases not driven by perfusion

Chris Baeken, Belgium

S-31-004

Clinical predictors of remission of depression after rTMS to the left DLPFC

Daniel Blumberger, Canada

T29: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

S-32

17:00–18:30

ENIGMA and the PGC: Large-scale studies of psychiatric genetics and brain imaging

Chair: Christopher Ching, USA

Co-Chair: Paul Thompson, USA

S-32-001

The ENIGMA Consortium: Large-scale studies of brain genetics and psychiatric illness

Paul Thompson, USA

S-32-002

ENIGMA Bipolar Working Group: Recent findings from the largest neuroimaging studies of Bipolar Disorder

Christopher Ching, USA

S-32-003

The Psychiatric Genomics Consortium: Recent findings from large-scale genetic studies of Bipolar Disorder

Ole Andreassen, Norway

S-32-004

ENIGMA CNV: Large-scale studies mapping genetic copy number variation to brain structure and risk for psychiatric illness

Ida Soenderby, Norway

T8: BIPOLAR DISORDERS: BASIC/CLINICAL

S-33

17:00–18:30

Canadian Network for Mood and Anxiety Treatments (CANMAT): Update of novel treatments and approaches for Bipolar Disorder

Chair: Roumen Milev, Canada

Co-Chair: Lakshmi N. Yatham, Canada

S-33-001

Novel treatment and approaches: Ketamine

Gustavo Vazquez, Canada

S-33-002

Learnings from the literature: An evidence informed review of the bipolar and microbiome clinical data

Valerie Taylor, Canada

S-33-003

CANMAT/ISBD Guidelines for Bipolar Disorder with mixed features

Lakshmi N. Yatham, Canada

S-33-004

Novel treatments and approaches: Ketogenic diet

Elisa Brietzke, Canada

T49: PSYCHOPHARMACOLOGY

S-34

17:00–18:30

Precision psychiatry: The case of treatment resistant schizophrenia

Chair: Jose Rubio, USA

Co-Chair: John M. Kane, USA

S-34-001

Towards the earlier identification and management of treatment resistant schizophrenia

John M. Kane, USA

S-34-002

The dynamic course of antipsychotic responsiveness over the course of illness in schizophrenia

Jose Rubio, USA

S-34-003

Antipsychotic treatment response and the neural circuitry of reward learning

Lucy Vanes, United Kingdom

S-34-004

If precision medicine is the answer, what is the question?

Philipp Homan, Switzerland

T8: BIPOLAR DISORDERS: BASIC/CLINICAL

S-35

17:00–18:30

Clearing the smoke: Cannabis, Mood Disorders and Schizophrenia. A CANMAT Symposium

Chair: Serge Beaulieu, Canada

Co-Chair: Valérie Tourjman, Canada

S-35-001

Dissecting patterns of genetic overlap between substance use and severe mental illness

Ole Andreassen, Norway

Preliminary Scientific Program / Symposia

S-35-002

A systematic review of Cannabis and Mood Disorder

Valérie Tourjman, Canada

S-35-003

Cannabis and Bipolar Disorder: The chicken or the egg?

Jean-Michel Aubry, Switzerland

S-35-004

Treatment of Cannabis and use disorders and Mood Disorders

Serge Beaulieu, Canada

► Wednesday, 30 June 2021

T14: DEPRESSION: BASIC / CLINICAL

S-36

07:30–09:00

The genomics of severe depression and ECT

Chair: Bernhard Baune, Germany

Co-Chair: Alessio Squassina, Italy

S-36-001

Genomics of severe MDD and ECT: Scientific rationale, scale standardized assessment and implementation of a worldwide effort

Bernhard Baune, Germany

S-36-002

A genome-wide association study of patients with a major depressive episode treated with ECT

Mikael Landén, Sweden

S-36-003

Molecular biomarkers for electroconvulsive therapy outcome: Present or future?

Alessandra Minelli, Italy

S-36-004

Correlation between baseline leukocyte telomere length and response to electroconvulsive therapy in major depressive disorder

Alessio Squassina, Italy

T57: STIMULATION METHODS (e.g., ECT, TMS, VNS, DBS)

S-37

07:30–09:00

Electroconvulsive therapy in Austria

Chair: Andreas Conca, Italy

Co-Chair: Jan Di Pauli, Austria

S-37-001

Epidemiology of ECT in middle Europe

Michael Grözinger, Germany

S-37-002

ECT implementation: Challenges prejustice and administration

Christa Rados, Austria

S-37-003

ECT in elderly: Clinical reality

Christoph Silberbauer, Austria

S-37-004

Relevant CNS biomarkers in the course of electroconvulsive therapy

Richard Frey, Austria

T49: PSYCHOPHARMACOLOGY

S-38

07:30–09:00

Minocycline in psychiatry

Chair: Olivia Dean, Australia

Co-Chair: Ishrat Husain, Canada

S-38-001

Mechanisms underpinning the neurobiological action of minocycline

Margaret Morris, Australia

S-38-002

Minocycline and schizophrenia

Imran B. Chaudhry, Pakistan

S-38-003

Minocycline and Bipolar Disorder

Ishrat Husain, Canada

S-38-004

Minocycline and depression

Olivia Dean, Australia

Symposia / Preliminary Scientific Program

T59: SUICIDE: BASIC / CLINICAL

S-39

07:30–09:00

From fieldwork to battlefield: Novel insights into the neurobiology of understanding, predicting and treating suicidal behaviour

Chair: Xenia Gonda, Hungary

Co-Chair: Jussi Jokinen, Sweden

S-39-001

“...half in love with easeful death”: Genome-wide association study of suicidal ideation in a deep-phenotyped population

Xenia Gonda, Hungary

S-39-002

Violent suicide attempt method: Gender differences, outcome and biomarkers of high-risk phenotype

Jussi Jokinen, Sweden

S-39-003

Psychobiology of suicidal behavior among combat veterans

Leo Sher, USA

S-39-004

Pharmacological treatment of suicidal behavior: Between tradition and innovation

Maurizio Pompili, Italy

T46: PSYCHONEUROIMMUNOLOGY

S-40

07:30–09:00

Involvement of the immune system in schizophrenia, depression and anxiety disorders

Chair: Hubertus Himmerich, United Kingdom

Co-Chair: Brenda Penninx, The Netherlands

S-40-001

Exploring cytokine networks in psychosis

Milica Borovcanin, Serbia

S-40-002

Immunometabolic insights from the Netherlands Study of Depression and Anxiety

Brenda Penninx, The Netherlands

S-40-003

Inflammation and the autonomous nervous system in depression

Frank M. Schmidt, Germany

S-40-004

Clinical applications of psychoimmunological research in depression and psychosis

Valeria Mondelli, United Kingdom

T14: DEPRESSION: BASIC / CLINICAL

S-41

07:30–09:00

Neurotrophins and their role in antidepressive therapy

Chair: Helge Frieling, Germany

Co-Chair: Tomi Rantamäki, Finland

S-41-001

Neurotrophin signaling and antidepressant action

Hansi Pathak, Germany

S-41-002

TrkB signaling and rapid-acting antidepressants

Tomi Rantamäki, Finland

S-41-003

Cannabidiol effects in depression and neurotrophin signaling

Sämia Joca, Denmark

S-41-004

Neurotrophin signaling and ECT

Alexandra Neyazi, Germany

T49: PSYCHOPHARMACOLOGY

S-42

11:00–12:30

Drug level monitoring with a focus on perinatal disorders: Clinical and research dilemmas

Chair: Tamas Kurimay, Hungary

Co-Chair: Angelika Wieck, United Kingdom

S-42-001

Benefits of therapeutic drug monitoring in guiding polytherapy in schizophrenia

Gellért Karvaly, Hungary

S-42-002

Clinical dilemmas on the psychopharmacological treatment during breastfeeding. What tools do we have for the risk-benefit evaluation? The use of therapeutic drug monitoring based scoring systems on drug safety in perinatal maternal mental health care

Anett Pelikan, Hungary

S-42-003

Monitoring atypical antipsychotics and antidepressants in breast milk – correlation with serum levels

Istvan Vincze, Hungary

S-42-004

When and how should we measure psychotropic plasma levels in pregnancy?

Angelika Wieck, United Kingdom

Preliminary Scientific Program / Symposia

T29: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

S-43

11:00–12:30

Staging of psychosis: Vision and challenges

Chair: Young-Chul Chung, Republic of Korea

Co-Chair: Dennis Hernaus, The Netherlands

S-43-001

Subcortical volume and cortical thickness findings from the ENIGMA CHR for Psychosis Working Group

Dennis Hernaus, The Netherlands

S-43-002

Neurocognitive deficits according to norms in adolescents with and without CHR states of psychosis

Chantal Michel, Switzerland

S-43-003

Different clinical features and neuroimaging markers in psychotic disorder NOS

Young-Chul Chung, Republic of Korea

S-43-004

Machine learning-based prediction for different clinical stages of SZ spectrum: A multisite cross-disease volumetric MRI analysis

Shinsuke Koike, Japan

T8: BIPOLAR DISORDERS: BASIC / CLINICAL

S-44

11:00–12:30

Metabolic perspective on neurocognition and illness progression in Bipolar Disorder

Chair: Bartholomeus Haarman, The Netherlands

Co-Chair: Flavio Kapczinski, Canada

S-44-001

Increased prevalence of metabolic syndrome in patients with Bipolar Disorder in LifeLines, a large population cohort

Benno Haarman, The Netherlands

S-44-002

Obesity as a risk factor for a more severe psychiatric illness course in STEP-BD

David Bond, USA

S-44-003

Short-term neurocognitive trajectories in Bipolar Disorder: Evidence from a follow-up family study

Vicent Balanza, Spain

S-44-004

Cognitive impairment in Bipolar Disorder with a novel brain mechanism involving changes in intracortical myelin

Benicio Frey, Canada

T1: ADDICTIVE DISORDERS

S-45

11:00–12:30

Appetite regulating peptides: An innovative neuroendocrinological therapy strategy for relapse prevention and craving in patients suffering from alcohol use disorder and tobacco dependence?

Chair: Alexander Glahn, Germany

Co-Chair: Anne Koopmann, Germany

S-45-001

The role of leptin and ghrelin during withdrawal in tobacco dependence and alcohol use disorder

Alexander Glahn, Germany

S-45-002

The impact of appetite-regulating ghrelin on alcohol use disorder

Anne Koopmann, Germany

S-45-003

Current results on the effects of oxytocin on nucleus accumbens connectivity in heavy social drinkers

Patrick Bach, Germany

S-45-004

Leptin, proopiomelanocortin and addictive disorders

Marc Muschler, Germany

T7: ARTIFICIAL INTELLIGENCE

S-46

11:00–12:30

Computerized procedures supporting diagnostics in psychiatry: Using AI to develop novel biomarker and diagnostic tool for psychiatric research and clinical practice

Chair: Jonathan Vogelgsang, Germany

Co-Chair: Torsten Klengel, Germany

S-46-001

Multivariable biomarkers of psychiatric risk through machine learning approaches

Andreas Meyer-Lindenberg, Germany

Symposia / Preliminary Scientific Program

S-46-002

Machine learning approaches to post-mortem phenotype brain donors: A new way to study molecular changes in the brain

Jonathan Vogelgsang, Germany

S-46-003

PET biomarker in AD, correlation between tau PET signal and cognition

Anne Maass, Germany

S-46-004

Computational phenotyping of patients with chronic psychiatric diseases

Justin Baker, USA

T56: STEM CELLS AND ORGANIDS

S-47

15:00–16:30

HiPSC technology: New approaches to dissect the molecular genetic mechanisms underlying schizophrenia

Chair: Florian Raabe, Germany

Co-Chair: Peter Falkai, Germany

Co-Chair: Moritz Rossner, Germany

S-47-001

CRISPR/Cas9 technology to understand the function of schizophrenia risk polymorphism

Kristen Brennand, USA

S-47-002

Modelling of inhibition deficits in schizophrenia with hiPSC technology

Sangmi Chung, USA

S-47-003

Functional systems genomics to dissect the polygenic architecture of schizophrenia

Michael Ziller, Germany

S-47-004

hiPSC organoids to model brain development in health and disease

Jürgen Knoblich, Austria

T26: MOLECULAR NEUROBIOLOGY

S-48

15:00–16:30

RNA biology in neuropsychiatry: From novel technologies to future precision psychiatry

Chair: Torsten Klengel, Germany

Co-Chair: Guia Guffanti, USA

S-48-001

Circulating non-coding RNAs as biomarker for neuropsychiatric disorder

Andre Fischer, Germany

S-48-002

Early life trauma affecting mental and physical health across generations

Isabelle Mansuy, Switzerland

S-48-003

LncRNA epigenetic signatures associated with childhood trauma and Post-traumatic Stress Disorder

Guia Guffanti, USA

S-48-004

CircRNAs in pre-clinical rodent models of stress-related disorders and human post-mortem brain

Torsten Klengel, Germany

T8: BIPOLAR DISORDERS: BASIC/CLINICAL

S-49

15:00–16:30

Recognizing and treating non-classical forms of Bipolar Disorder

Chair: Heinz Grunze, Germany

Co-Chair: Allan Young, United Kingdom

S-49-001

Chronic and subsyndromal Bipolar Disorder

Konstantinos Fountoulakis, Greece

S-49-002

Mixed Bipolar II Disorder

Trisha Suppes, USA

S-49-003

Rapid and ultradian cycling

Allan Young, United Kingdom

S-49-004

Mixed features in depression

Norma Verdolini, Spain

Preliminary Scientific Program / Symposia

T57: STIMULATION METHODS (e.g., ECT, TMS, VNS, DBS)

S-50

15:00–16:30

Electroconvulsive therapy beyond depression: Specific populations and (yet) rare indications

Chair: David Zilles-Wegner, Germany

Co-Chair: Alexander Sartorius, Germany

S-50-001

ECT and neurodegenerative disorders

Alexander Sartorius, Germany

S-50-002

ECT in Post-traumatic Stress Disorder

Ulrike Schmidt, Germany

S-50-003

ECT in pregnancy

David Zilles-Wegner, Germany

S-50-004

ECT in child and adolescent psychiatry

Henrik Uebel-von Sandersleben, Germany

T1: ADDICTIVE DISORDERS

S-51

18:30–20:00

Behavioral addictions: Brain imaging findings and their translation to clinical practice

Chair: Marc Potenza, USA

Co-Chair: Florence Thibaut, France

S-51-001

Internet gaming disorder: Treatment, neurobiology and gender considerations

Marc Potenza, USA

S-51-002

The association between excessive use of screens and cognition, emotion and the brain

Aviv Weinstein, Israel

S-51-003

Neural activity in individuals with buying-shopping disorder during presentation of shopping-related cues

Patrick Trotske, Germany

S-51-004

Chemsex and compulsive sexual behaviors

Florence Thibaut, France

T26: MOLECULAR NEUROBIOLOGY

S-52

18:30–20:00

Biomarkers of response to IV Ketamine for depression

Chair: Sagar Parikh, USA

Co-Chair: Susannah Tye, Australia

S-52-001

Insulin-stimulated mTOR activation and antidepressant response to Ketamine

Susannah Tye, Australia

S-52-002

Clinical biomarkers of response to Ketamine

Gregor Hasler, Switzerland

S-52-003

Does inflammation mediate Ketamine response? Analysis of kynurenine metabolites and cytokines in patients receiving Ketamine

Lena Brundin, USA

S-52-004

The Kynurenine Pathway: Implications for mood disorders and suicidality

Sophie Erhardt, Sweden

T10: CHRONOBIOLOGY AND PSYCHIATRY

S-53

18:30–20:00

Chronobiology: From basic concepts to clinical practice in Mood Disorders

Chair: Serge Beaulieu, Canada

Co-Chair: Outi Linnaranta, Finland

S-53-001

There will be light! Standardizing Melatonin, actigraphy and clinical measures in Bipolar Disorders research: Recommendations from the ISBD Chronobiology Task Force

Benicio N. Frey, Canada

S-53-002

Clinical correlates of disrupted circadian rhythm in Bipolar Disorders

Outi Linnaranta, Finland

S-53-003

Personalization of the treatment to the “sleep” dimension

Pierre Alexis Geoffroy, France

S-53-004

Are we ready to use chronobiology in our practice?

Serge Beaulieu, Canada

Symposia / Preliminary Scientific Program

T49: PSYCHOPHARMACOLOGY

S-54

18:30–20:00

Benefit of Ketamine in clinical practice: Current perspectives

Chair: Arun Ravindran, Canada

Co-Chair: Shehan Williams, Sri Lanka

S-54-001

Does Ketamine improve suicidal behaviour?

Woon Sy-Cherng Luke, Malaysia

S-54-002

Benefits and challenges of Ketamine in low and middle income countries

Shehan Williams, Sri Lanka

S-54-003

Guidelines for use of Ketamine for practicing clinicians

Raymond Lam, Canada

T49: PSYCHOPHARMACOLOGY

S-55

18:30–20:00

The present and future of biological psychiatry through the eyes of residents

Chair: Afzal Javed, United Kingdom

Co-Chair: Konstantinos Fountoulakis, Greece

S-55-001

Neurological soft signs in schizophrenia

Efi Tsomaka, Belarus

S-55-002

TBD

Tatsiana Skuhareuskaya, Belarus

S-55-003

Heart rate variability associated with intranasal esketamine add-on therapy in depression

Alexandre Margueron, Switzerland

S-55-004

Covid and mental health in the metropolitan area of Rome

Benedetta Montalbani, Italy



Preliminary Scientific Program / Workshops, Educational Sessions

Workshops

► Tuesday, 29 June 2021

T59: SUICIDE: BASIC / CLINICAL

WS-01

09:30–11:00

**Immune system and suicidal behaviour:
What do we know?**

Chair: Teo Postolache, USA

Co-Chair: Dan Rujescu, Germany

WS-01-001

**Immune mediated triggers and predispositions of
suicide and its risk factors**

Teo Postolache, USA

WS-01-002

**Haematopoietic modulation in patients with major
depressive episodes and suicide attempts**

Pilar A. Saiz, Spain

WS-01-003

**Linking unfolded protein response to inflammation
and suicidality**

Yogesh Dwivedi, USA

WS-01-004

DNA methylation in suicide victims

Alina Videtic Paska, Slovenia

T14: DEPRESSION: BASIC / CLINICAL

WS-02

17:00–18:30

**Next-step treatment considerations in patients with
treatment-resistant depression that respond to low-
dose intravenous Ketamine**

Chair: Sagar Parikh, USA

WS-02-001

**IV Ketamine: Frequency of infusions and dosing
modifications for long term use of IV Ketamine**

Patricio Riva-Posse, USA

WS-02-002

ECT or TMS as a follow-up to IV Ketamine

Venkat Bhat, Canada

WS-02-003

Oral Ketamine strategies in treating depression

Sagar Parikh, USA

WS-02-004

**Psychotherapy after receiving IV Ketamine:
Integrating neurobiological and clinical findings**

Gregor Hasler, Switzerland

Educational Sessions

► Monday, 28 June 2021

ES-01

07:30–09:00

How to design a translational (clinical) study

Chair: Alkomiet Hasan, Germany

ES-02

15:30–17:00

Understanding and performing meta-analysis

Chair: Alessandro Serretti, Italy

► Tuesday, 29 June 2021

ES-03

09:30–11:00

Understanding and designing genetic studies

Chair: Dan Rujescu, Germany

ES-04

13:30–15:00

Basics of biostatistics

Chair: Nikolaos Koutsouleris, Germany

► Wednesday, 30 June 2021

ES-05

15:00–16:30

Understanding and designing imaging studies

Chair: Tobias Kaufmann, Germany

Topics

The scientific program of the 15th World Congress of Biological Psychiatry will cover the following topics. Within each topic the track may be basic, clinical, interface or conceptual:

- | | |
|--|---|
| 1 Addictive Disorders | 32 Nutritional Psychiatry and the Microbiome |
| 2 ADHD | 33 Obsessive-Compulsive Disorders: Basic/Clinical |
| 3 Antidepressants: Basic/Clinical | 34 Omics |
| 4 Antipsychotics: Basic/Clinical | 35 Pain: Basic/Clinical |
| 5 Anxiety Disorders: Basic/Clinical | 36 Panic Disorders: Basic/Clinical |
| 6 Anxiolytics: Basic/Clinical | 37 Personality Disorders: Basic/Clinical |
| 7 Artificial Intelligence | 38 Pharmacoeconomics |
| 8 Bipolar Disorders: Basic/Clinical | 39 Pharmacogenetics |
| 9 Childhood & Adolescent Disorders: Basic/Clinical | 40 Placebo/Nocebo |
| 10 Chronobiology and Psychiatry | 41 Post Traumatic Stress Disorders |
| 11 Cognitive Neuroscience | 42 Precision Psychiatry |
| 12 Consultation and Liaison Psychiatry | 43 Pregnancy, Postpartum and Newborn – Mental Health Issues |
| 13 Dementia: Basic/Clinical | 44 Premenstrual Syndrome: Basic/Clinical |
| 14 Depression: Basic/Clinical | 45 Psychogeriatrics |
| 15 Digital Phenotyping | 46 Psychoneuroimmunology |
| 16 Drug Development | 47 Psycho-Oncology |
| 17 Eating Disorders: Basic/Clinical | 48 Psychopathology |
| 18 Emergency Psychiatry | 49 Psychopharmacology |
| 19 Epidemiology | 50 Psychotherapy: Biological Mechanisms |
| 20 Ethics in Biological Psychiatry | 51 Sars-CoV-2 |
| 21 Forensic Psychiatry | 52 Schizophrenia and Other Psychosis: Basic/Clinical |
| 22 Genetics | 53 Sexual Disorders: Basic/Clinical |
| 23 Light Therapy | 54 Sleep Disorders: Basic/Clinical |
| 24 Machine Learning and Big Data | 55 Somatoform Disorders: Basic/Clinical |
| 25 Mental Retardation or Chromosomal Aberrations: Basic/Clinical | 56 Stem Cells and Organoids |
| 26 Molecular Neurobiology | 57 Stimulation Methods (e.g., ECT, TMS, VNS, DBS) |
| 27 Mood Stabilizers: Basic/Clinical | 58 Stress: Basic/Clinical |
| 28 Neuroendocrinology | 59 Suicide: Basic/Clinical |
| 29 Neuroimaging: Genetic, Functional, Structural | 60 Violence: Basic/Clinical |
| 30 Neuropathology | 61 Virtual Care |
| 31 Neurophysiology | 62 Miscellaneous |

Call for Abstracts for Free Communications and Posters

Extended deadline for abstract submission:

9 March 2021

Notification of acceptance/rejection: April 2021

The International Scientific Program Committee of the WFSBP 2021 Congress invites you to participate actively in this congress which will be an extraordinary occasion for the exchange of thoughts and experiences. We look forward to receiving abstracts online for consideration and inclusion in the scientific program as Free Communications or Posters.

The submitted abstracts should give a brief description of the title and topic. All abstracts will be reviewed by the International Scientific Program Committee.

The reviewers will judge the abstracts according to the relevance to the WFSBP, standard of English, objectivity of statement, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall impression.

All accepted abstracts will be grouped by category topics into thematic sessions and will be published online on the congress website.

The deadline for abstract submission is

9 March 2021

FREE COMMUNICATIONS

Free Communications will be selected by the International Scientific Program Committee after abstract submissions have been reviewed.

Only 1 Free Communication abstract may be submitted per author.

POSTERS

Accepted posters will be part of the virtual poster exhibition which is accessible for all registered delegates throughout the congress.

A maximum of 2 abstracts may be submitted per author (posters and FC combined).

Please note that accepted abstracts will be published only after completed registration and payment of the congress registration fee. The acceptance of submitted abstracts simultaneously results in binding registration of the speaker to attend the conference. **The registration fee must be paid immediately** upon receipt of the abstract acceptance, at the **latest by 20 April 2021**. Authors who have not paid the registration fee by that date will not be included in the scientific program.

GUIDELINES FOR THE PREPARATION OF ABSTRACTS

- ▶ Please choose a title that clearly indicates the content of the contribution.
- ▶ Please avoid abbreviations in the title (exception: scientific terms). Abbreviations may be used in the text if they are defined when used first.
- ▶ Please make sure to use proper English language.
- ▶ Please refrain from spelling abstract titles and co-authors' names in capital letters.
- ▶ The author's name (full first name, family name) and place of work (institution, city, country) should be indicated in the respective form fields, not in the abstract title.
- ▶ Degrees, titles, street addresses and acknowledgements of support should be omitted in the abstract title and text.
- ▶ Please choose a topic from the topic list.
- ▶ Abstracts are to be submitted in English, the official language of the WFSBP 2021 Congress and should not exceed a maximum of **300 words**.
- ▶ A disclosure of the existence of any significant financial interest or other affiliations with a funding organization or with a commercial supporter of the session and / or provider of commercial services is required.
- ▶ All abstracts will be published online in the scientific program of the WFSBP Congress from April 2021.
- ▶ **Only 1 Free Communication abstract / Young Investigator Award Abstract may be submitted per author.**
- ▶ **A maximum of 2 abstracts may be submitted per author (posters and FC combined).**

TO PROVIDE MAXIMUM INFORMATION IN THE ABSTRACT PLEASE

- ▶ State the specific **objective** of the study (indicate the purpose of the study or the hypothesis that was tested)
- ▶ State the **methods** used, if pertinent (include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis. If references are needed, they should be given in the text)
- ▶ Summarize the **results** obtained (present as clearly as possible the outcome of the study and statistical significance if appropriate)
- ▶ State the **conclusions** reached (briefly discuss the data and emphasize the significance of the results)

- ▶ Ensure that the abstract does not contain spelling, grammatical or scientific errors, as it will be reproduced exactly as submitted. Submitted abstracts will not be edited in any way. If the abstract does not fulfill the necessary requirements it cannot be published.
- ▶ Make sure that references are given in the text.

For any further assistance, please contact the congress and exhibition office:

CPOHANSER[®]
SERVICE

Phone: +49-30-300 669-0
wfsbp2021@cpo-hanser.de

We organize your success

CPO HANSER SERVICE is specialized in the field of Conference, Event, Destination Management and, Association Management and has been organizing events of any size throughout Germany and worldwide for more than 35 years.

CPOHANSER[®]
SERVICE

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design

BERLIN

Paulsborner Str. 44
14193 Berlin, Germany
phone +49-30-300 669 0
fax +49-30-305 73 91
email berlin@cpo-hanser.de

HAMBURG

Zum Ehrenhain 34
22885 Barsbüttel, Germany
phone +49-40-670 882 0
fax +49-40-670 32 83
email hamburg@cpo-hanser.de

www.cpo-hanser.de



Format Descriptions of the Scientific Sessions

PLENARY LECTURES

Plenary Lectures are 60-minute sessions held by renowned experts. The speakers are chosen among the most prominent researchers in their respective fields.

DEBATES

Debates are intended to offer a platform for a lively yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) will state their opinions on different subjects.

WFSBP TASK FORCE SYMPOSIA

WFSBP Task Forces will submit symposia organized by their key members on issues related to their field of special expertise. Those symposia will be included in the scientific program and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

SYMPOSIA

Symposia are selected, covering basic, clinical, interface, and conceptual topics of Biological Psychiatry. Symposia are 90-minute sessions and will be organized and chaired by the experts whose proposals are accepted by the International Scientific Program Committee.

WORKSHOPS

Workshops are 90-minute highly interactive sessions with an educational focus. This format is designed to give specific regions a platform for presentation and networking.

FREE COMMUNICATIONS

Authors are invited to submit abstracts on their latest research findings. All submitted abstracts will be reviewed and the best will be selected and allocated to Free Communication Sessions.

POSTERS

Accepted posters will be part of the virtual poster exhibition which is accessible for all registered delegates throughout the congress.

EDUCATIONAL SESSIONS

(Young Investigator Award Sessions)

These sessions are dedicated to young researchers up to 40 years of age who will be pre-selected via an application process. Herewith the WFSBP is promoting education for talented young researchers. Interactional and practical learning is in the focus of these sessions. The educational sessions are open to all congress delegates.

INDUSTRY SPONSORED SYMPOSIA

These 90-minute sessions are fully integrated into the congress. The sessions are organized and executed by the pharmaceutical industry by unrestricted educational grants.

CME CREDITS

An application will be made to the UEMS EACCME for accreditation of this event. CME credits will be granted for live viewing only, not for on-demand viewing.

The UEMS EACCME CME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). More information will become available prior to the congress on the congress website <http://www.wfsbp-congress.org>.



On top of the 3 congress days, all WFSBP sessions will be available on demand for 2 months after the congress via the congress website.

WFSBP Awards

The following WFSBP Awards will be delivered and presented during the 15th World Congress of Biological Psychiatry 2021.

► WFSBP Lifetime Achievement Award in Biological Psychiatry

The WFSBP Lifetime Achievement Award in Biological Psychiatry is intended for senior research scientists (MD, PhD or equivalent) whose lifework has significantly influenced today's field of Biological Psychiatry. This award is open to members and non-members of the WFSBP. It consists of a monetary grant of EUR 1,000.

► WFSBP Award for Scientific Excellence of the WFSBP Host

The WFSBP Award for Scientific Excellence of the WFSBP Host is dedicated to an outstanding researcher in the field of Biological Psychiatry originating from the host country of the World Congress of Biological Psychiatry. This award consists of a monetary grant of EUR 1,000.

► WFSBP Research Prize

The WFSBP Research Prize is intended for WFSBP members (MD, PhD or equivalent) whose current scientific work has had an important impact in the field of clinical and/or basic research in the area of Biological Psychiatry. This prize consists of a monetary grant of EUR 1,000.

► WFSBP Award for Excellence in Education

The WFSBP Award for Excellence in Education is to acknowledge outstanding and innovative education in Biological Psychiatry including the implementation of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved education in all fields of psychiatry. This award consists of a monetary grant of EUR 1,000.

► WFSBP Young Investigator Awards

WFSBP is offering Awards to young investigators to attend the WFSBP biennial congress and the special educational sessions. The Award includes a free registration to the WFSBP Congress.

Psychiatrists or basic researchers under the age of 40 are eligible to apply.

The selection is competitive. The application should include the following:

1. A letter from the candidate applying for the Award with a summary of career goals and interest in Biological Psychiatry
 2. A letter from a mentor or the president of the national WFSBP affiliate Society outlining the candidate's achievements and how the award will support the candidate's career in Biological Psychiatry
 3. A Curriculum Vitae
- Priority will be given to candidates:
- a) with demonstrated interest in Biological Psychiatry
 - b) with history of interest in research and some track record of publications
 - c) that have submitted an abstract for a poster or a free communication
 - d) from developing countries

The Awardees are expected to attend all five WFSBP educational sessions.

Deadline for submission of application: 9 March 2021.

The submission including all required documents must be sent to the congress office via email:

wfsbp2021@cpo-hanser.de

Congress Information

Congress registration for the 15th World Congress of Biological Psychiatry is available via the congress website at www.wfsbp-congress.org.

Registration and payment received	Early registration by 9 March 2021 EUR	Late registration by 30 April 2021 EUR	On-site registration after 30 April 2021 EUR
WFSBP Members	250	350	450
Non-Members	350	450	550
Chairs, co-chairs, speakers of accepted symposia and workshops	130		
Participants from Low-Income Countries*	90	190	290
Trainee/Student**	90	190	290

* According to the Low-Income Countries defined by the World Bank. Please see the list on the WFSBP website www.wfsbp-congress.org

** Trainee/Student status must be confirmed by certificate in writing by head of department, and is applicable only for participants born after 1 January 1986. Please send your certificate by email to: CPO HANSE SERVICE GmbH, Email: wfsbp2021@cpo-hanser.de

PAYMENT

When registering for the WFSBP 2021 Congress, please arrange for payment of the registration fee. All payments should be made in EURO. You may choose between two payment methods: **credit card payment** or **bank transfer**. Especially for payment made from outside Germany where the congress office is based, we strongly recommend credit card payments as charges for bank transfers may apply twice, once in the country of origin and a second time in Germany.

Please choose one method of payment:

Credit card: AMEX, MasterCard or VISA

or bank transfer to the congress bank account:

Hanser & Co GmbH w/WFSBP 2021 ZB

Deutsche Bank AG

Bank Code: 1007 0024

Account Number: 108 96 97 41

BIC: DEUT DE DB BER

IBAN: DE 59 1007 0024 0108 96 97 41

CONFIRMATION

Upon receipt of the registration and the corresponding payment, the congress office will send a confirmation which also serves as an invoice. Please show this confirmation of registration at the congress counter when picking up your congress materials.

CANCELLATION OF CONGRESS PARTICIPATION

Please see the general terms and conditions on the congress website www.wfsbp-congress.org.

General Information

CONGRESS AND EXHIBITION OFFICE

CPO HANSER
SERVICE

Phone: +49-30-300 669-0

Email: wfsbp2021@cpo-hanser.de

CONGRESS INFORMATION SYSTEM/ CO CONGRESS ONLINE 2.0®

The web based Congress Information System CO CONGRESS ONLINE 2.0® has been installed at www.wfsbp-congress.org

Prior to the congress, CO CONGRESS ONLINE 2.0® will provide information on:

- ▶ Preparation of the congress
- ▶ List of topics
- ▶ Call for abstracts
- ▶ Invited speakers and invited conveners of symposia
- ▶ Preliminary scientific program
- ▶ Accepted abstracts
- ▶ List of exhibitors
- ▶ Information about the main sponsors
- ▶ Special news

In due time, the final program will be published on CO CONGRESS ONLINE 2.0® which enables each participant to create her / his personal congress program schedule. CO CONGRESS ONLINE 2.0® offers an extensive congress service.

CURRENCY

The Euro is the official congress currency.

VIRTUAL POSTERS

Posters can be viewed virtually on the congress platform for the duration of the congress and for 2 months after the congress.

VIRTUAL EXHIBITION

The WFSBP Virtual Congress will include a virtual exhibition. Potential exhibitors can request an exhibition/ sponsoring brochure from the exhibition office CPO HANSER SERVICE.

Email: wfsbp2021@cpo-hanser.de

Discover Current Research in the Exciting Cross-Disciplinary Field of the Microbiome-Gut-Brain-Axis



Psychiatry and
Psychology

ORDER HERE



karger.com/MP5



Karger

RESEARCH



Dates to remember

- | | |
|----------------------|--|
| 9 March 2021 | Abstract submission deadline Posters / Free Communications |
| 30 April 2021 | Deadline late registration |

ACKNOWLEDGEMENTS

The WFSBP gratefully acknowledges the support of the following companies (as of February 2020): <https://www.wfsbp-congress.org/sponsors-exhibitors/acknowledgements.html>

Premium Sponsor:



Main Sponsor:



General Sponsor:



www.wfsbp-congress.org